Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: Results from the SWEFOT trial

Karen Hambardzumyan*, Rebecca J. Bolce, Saedis Saevarsdottir, Kristina Forslind, Johan K. Wallman, Scott E. Cruickshank, Eric H. Sasso, David Chernoff, Ronald F. Van Vollenhoven

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Objectives: In rheumatoid arthritis (RA), predictive biomarkers for subsequent radiographic progression (RP) could improve therapeutic choices for individual patients. We previously showed that the multibiomarker disease activity (MBDA) score in patients with newly diagnosed RA identified patients at risk for RP. We evaluated the MBDA score at multiple time-points as a predictor of RP during 2 years of follow-up. Methods: A subset of patients with RA (N=220) from the Swedish Farmacotherapy (SWEFOT) trial were analysed for MBDA score, disease activity score of 28 joints (DAS28), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at baseline (BL), month 3 and year 1, for predicting RP based on modified Sharp/van der Heijde scores at BL, year 1 and year 2. Results: Patients with persistently low MBDA (<30) scores or those with a decrease from moderate (30-44) to low MBDA scores, did not develop RP during 2 years of follow-up. The highest risk for RP during 2 years of follow-up (42%) was observed among patients with persistently high (>44) MBDA scores. Among methotrexate non-responders with a high MBDA score at BL or month 3, significantly more of those who received triple therapy had RP at year 2 compared with those who received antitumour necrosis factor therapy. Conclusions: Measuring the MBDA score both before and during treatment in RA was useful for the assessment of individual patient risk for RP during 2 years of follow-up. In comparison with low CRP, ESR or DAS28, a low MBDA score at any time-point was associated with numerically lower proportions of RP.

Original languageEnglish
Article numbere000197
JournalRMD Open
Volume2
Issue number1
DOIs
Publication statusPublished - 2016

Bibliographical note

Funding Information:
The work was supported in part by a grant from the Swedish Rheumatism Association. Some of the authors were supported by clinical research funds from Stockholm County (ALF funds). RFvV received a grant/research support from: AbbVie, BMS, GSK, Pfizer, Roche, UCB; was a consultant for: AbbVie, Biotest, BMS, Crescendo Bioscience, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, Vertex.

Fingerprint

Dive into the research topics of 'Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: Results from the SWEFOT trial'. Together they form a unique fingerprint.

Cite this